Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 1013

Next Previous
Drug Profile

MT 1013

Alternative Names: MT-1013

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shaanxi Micot Technology Co
  • Class Peptides
  • Mechanism of Action Calcium-sensing receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Secondary hyperparathyroidism
  • No development reported Calcium metabolism disorders; Phosphorus metabolism disorders

Most Recent Events

  • 19 Aug 2026 Everest Medicines expects approval for MT 1013 in 2028
  • 30 Apr 2026 Everest Medicines completes enrolment in its phase III trial for Secondary hyperparathyroidism in China (IV)
  • 05 Jan 2026 Everest medicines in-licenses MT 1013 from Shaanxi Micot Pharmaceutical Technology in China and Asia-Pacific excluding Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top